SNP 610

Drug Profile

SNP 610

Alternative Names: SNP-610

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinew Pharma
  • Class Hepatoprotectants; Immunoconjugates
  • Mechanism of Action Enzyme modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 19 Jul 2017 SNP 610 is available for licensing as of 19 Jul 2017.
  • 19 Jul 2017 Sinew Pharma announces intention to submit applications for orphan drug designation, fast track designation and breakthrough designation to US FDA (Sinew Pharma pipeline, July 2017)
  • 19 Jul 2017 Sinew Pharma plans a phase IIa (proof-of-concept) trial for Non alcoholic steatohepatitis in Taiwan (PO) (Sinew Pharma pipeline, July 2017) (NCT03468556)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top